The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of the anti-TROP2 antibody-drug conjugate (ADC) IBI130 in patients (pts) with advanced triple-negative breast cancer (TNBC) and other solid tumors: Results from the phase 1 study.
 
Fan Wu
No Relationships to Disclose
 
Qian Chu
No Relationships to Disclose
 
Qin Xu
No Relationships to Disclose
 
Fuming Qiu
No Relationships to Disclose
 
Jin Yang
No Relationships to Disclose
 
Christina Teng
Employment - Scientia Clinical Research
 
Guohui Han
No Relationships to Disclose
 
Xi Shi
No Relationships to Disclose
 
Vineet Kwatra
No Relationships to Disclose
 
Hongtao Li
No Relationships to Disclose
 
Caigang Liu
No Relationships to Disclose
 
Yuping Sun
Honoraria - AstraZeneca; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Pfizer; Roche
 
Huihui Li
No Relationships to Disclose
 
Fanfan Li
No Relationships to Disclose
 
Xiaochen Zhang
No Relationships to Disclose
 
Andrew Parsonson
Research Funding - BeiGene (Inst); DualityBio (Inst); Innovent Biologics (Inst); Jiangsu Hengrui Medicine (Inst); Multitude Therapeutics (Inst)
 
Jianyun Nie
No Relationships to Disclose
 
Faliang Xu
No Relationships to Disclose
 
Hui Zhou
Employment - Innovent Biologics
 
Yongmei Yin
No Relationships to Disclose